Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FGM5F
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,883
Award facts
- Contract value 100% obligated
- $30,883.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $30,883.26 delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors. This firm fixed-price delivery order, with an ultimate completion date of January 8, 2026, represents a single transaction under a larger pharmaceutical supply vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with parent company Cencora, Inc. (doing business as AmerisourceBergen) overseeing operations. This award was not designated as a set-aside contract and was competitively awarded through open procurement.
This delivery order falls under AmerisourceBergen's significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which functions as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The broader IDC enables the company to supply a vast range of pharmaceutical and medical products, including specialty medications, brand-name and generic drugs, and medical devices to support Defense Health Agency and other federal healthcare systems worldwide. Dupixent is a biologic immunosuppressant commonly used to treat moderate-to-severe atopic dermatitis, asthma, and eosinophilic conditions, reflecting the breadth of specialty pharmaceutical products distributed through DLA's medical supply chain to support military personnel and veteran healthcare needs.
Quick answers
Who was awarded contract SPE2DR26FGM5F?
SPE2DR26FGM5F was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FGM5F worth?
The government has obligated $30,883 on SPE2DR26FGM5F.
Is contract SPE2DR26FGM5F an order under another contract?
Yes. SPE2DR26FGM5F is a delivery order under SPE2DR25D1002, an indefinite delivery contract.
Was contract SPE2DR26FGM5F competed?
The extent of competition for SPE2DR26FGM5F was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award